Evidence map›Paper›PMID 39366988›Full record

ArticleScientific reports2024

Exploring the ability of the MD+FoldX method to predict SARS-CoV-2 antibody escape mutations using large-scale data.

L América Chi, Jonathan E Barnes, Jagdish Suresh Patel, F Marty Ytreberg

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

L América ChiInstitute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA.
Jonathan E BarnesInstitute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA.
Jagdish Suresh PatelInstitute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA. jspatel@uidaho.edu.
F Marty YtrebergInstitute for Modeling Collaboration and Innovation, University of Idaho, Moscow, ID, 83844, USA. ytreberg@uidaho.edu.

Funding

Sequence-structure-function relationships in human visual photopigmentsP20GM104420 · NIGMS · UNIVERSITY OF IDAHO · PI MILLER, CRAIG R · 2015 to 2024
$22.9M
NIGMS NIH HHS P20 GM104420NIH HHS P20GM104420
6 · The paper itself

Abstract

Antibody escape mutations pose a significant challenge to the effectiveness of vaccines and antibody-based therapies. The ability to predict these escape mutations with computer simulations would allow us to detect threats early and develop effective countermeasures, but a lack of large-scale experimental data has hampered the validation of these calculations. In this study, we evaluate the ability of the MD+FoldX molecular modeling method to predict escape mutations by leveraging a large deep mutational scanning dataset, focusing on the SARS-CoV-2 receptor binding domain. Our results show a positive correlation between predicted and experimental data, indicating that mutations with reduced predicted binding affinity correlate moderately with higher experimental escape fractions. We also demonstrate that higher precision can be achieved using affinity cutoffs tailored to distinct SARS-CoV-2 antibodies from four different classes rather than a one-size-fits-all approach. Further, we suggest that the quartile values of optimized cutoffs reported for each class in this study can serve as a valuable guide for future work on escape mutation predictions. We find that 70% of the systems surpass the 50% precision mark, and demonstrate success in identifying mutations present in significant variants of concern and variants of interest. Despite promising results for some systems, our study highlights the challenges in comparing predicted and experimental values. It also emphasizes the need for new binding affinity methods with improved accuracy that are fast enough to estimate hundreds to thousands of antibody-antigen binding affinities.

Indexed as

Antibodies, ViralCOVID-19MutationSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingHumansMolecular Dynamics SimulationProtein BindingAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2AntibodyDMSEscape mutationFoldXMDSARS-CoV-2

Identifiers

PMID39366988
PMCPMC11452645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.